- LONDON (Reuters Health) -
Britain's medicines' agency announced on Tuesday a new study to find out
if people taking antidepressant drugs are at increased risk of suicide.
-
- The Medicines and Healthcare Products Regulatory Agency
said the study would estimate the risk of suicide, suicidal thoughts, non-fatal
overdose and self-laceration in patients taking selective serotonin re-uptake
inhibitors (SSRI) and tricyclic antidepressants (TCA).
-
- Britain has taken the lead in reviewing the safety of
the newer SSRI class of drugs following reports that some depressed patients
turn violent or suicidal after starting medication.
-
- A safety review in children last year resulted in the
UK agency advising doctors not to prescribe the majority of SSRIs to under-18
year-olds as the risks of treatment were found to outweigh the benefits.
-
- The new study will follow patients of all ages up to
90 years old who were diagnosed with depression between 1995 and 2001.
-
- Relative risks of suicide and other adverse events will
be calculated for SSRI and TCA treatment versus no drug treatment, SSRI
versus TCA treatment, and for each SSRI compared with GlaxoSmithKline's
SSRI Seroxat/Paxil (paroxetine).
-
- Officials were not immediately available to explain why
the Glaxo product had been singled out, though one possible explanation
is that it is the most commonly prescribed SSRI.
-
- Drug companies insist that millions of patients have
been prescribed SSRIs without suffering major adverse events and that any
suicidal thoughts are the result of their depression rather than the treatment.
-
- Copyright © 2003 Reuters Limited. All rights reserved.
Republication or redistribution of Reuters content is expressly prohibited
without the prior written consent of Reuters. Reuters shall not be liable
for any errors or delays in the content, or for any actions taken in reliance
thereon.
|
